1
|
Lu K, Bhat M, Peters S, Mitra R, Oberyszyn T, Basu S. Suppression of beta 2 adrenergic receptor actions prevent UVB mediated cutaneous squamous cell tumorigenesis through inhibition of VEGF-A induced angiogenesis. Mol Carcinog 2021; 60:172-178. [PMID: 33482042 PMCID: PMC7889723 DOI: 10.1002/mc.23281] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2020] [Revised: 01/06/2021] [Accepted: 01/07/2021] [Indexed: 12/18/2022]
Abstract
Although beta 2 adrenergic receptors (β2 ADR) are present in the keratinocytes, their role in cutaneous squamous cell tumorigenesis needs to be ascertained. For the first time, we report here that selective β2 ADR antagonists by inhibiting β2 ADR actions significantly retarded the progression of ultraviolet B (UVB) induced premalignant cutaneous squamous cell lesions. These antagonists acted by inhibiting vascular endothelial growth factor-A (VEGF) mediated angiogenesis to prevent UVB radiation-induced squamous cell carcinoma of the skin.
Collapse
MESH Headings
- Adrenergic beta-1 Receptor Agonists/pharmacology
- Adrenergic beta-2 Receptor Antagonists/pharmacology
- Animals
- Butoxamine/pharmacology
- Humans
- Keratinocytes/metabolism
- Keratinocytes/radiation effects
- Male
- Mice, Inbred Strains
- Neoplasms, Radiation-Induced/blood supply
- Neoplasms, Radiation-Induced/drug therapy
- Neoplasms, Radiation-Induced/etiology
- Neoplasms, Squamous Cell/blood supply
- Neoplasms, Squamous Cell/drug therapy
- Neoplasms, Squamous Cell/etiology
- Neovascularization, Pathologic/drug therapy
- Neovascularization, Pathologic/metabolism
- Receptors, Adrenergic, beta-2/metabolism
- Skin Neoplasms/blood supply
- Skin Neoplasms/drug therapy
- Skin Neoplasms/etiology
- Ultraviolet Rays/adverse effects
- Vascular Endothelial Growth Factor A/metabolism
- Xamoterol/pharmacology
- Mice
Collapse
Affiliation(s)
- Kai Lu
- Department of Pathology, Ohio State University, Columbus,
USA
| | - Madhavi Bhat
- Department of Pathology, Ohio State University, Columbus,
USA
| | - Sara Peters
- Department of Pathology, Ohio State University, Columbus,
USA
| | - Rita Mitra
- KPC Medical College, Kolkata, India. USA
| | - Tatiana Oberyszyn
- Department of Pathology, Ohio State University, Columbus,
USA
- Comprehensive Cancer Center, Ohio State University,
Columbus, USA
| | - Sujit Basu
- Department of Pathology, Ohio State University, Columbus,
USA
- Comprehensive Cancer Center, Ohio State University,
Columbus, USA
- Division of Medical Oncology, Department of Internal
Medicine, Ohio State University, Columbus, USA
| |
Collapse
|
2
|
Abikhair M, Roudiani N, Tober K, Oberyszyn T, Krueger J, Felsen D, Carucci J. 244 Transplant immunosuppression drives catastrophic carcinomatosis through IL 22. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
3
|
Braddom A, Richmond T, Sheetz T, Reese E, Tessari A, Tober K, Burd CE, De Lorenzo C, Martin EW, Coppola V, Tweedle MF, Oberyszyn T, Croce CM, Palmieri D. Abstract C171: Human anti-Nucleolin recombinant immunoagents as new potential tools for melanoma treatment. Mol Cancer Ther 2015. [DOI: 10.1158/1535-7163.targ-15-c171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Immunotherapy and immune-based anti-cancer molecules represent a valid strategy to fight cancer. However, the choice of tumor-specific surface molecules for the selective targeting of cancer cells still represents a critical step in the study design for the development of new therapeutic approaches. Notably, the development of phage-display technology for the selection of fully human single chain antibody fragments (scFvs) and complete antibodies directed toward tumor-associated antigens has represented a significant advancement for immunotherapy.
Nucleolin (NCL) is one of the most abundant non-ribosomal proteins in the nucleolus. NCL is frequently up-regulated in cancer and in cancer-associated endothelial cells compared to normal tissues, where it is also present on the cell surface. Altered NCL expression and localization results in oncogenic effects such as stabilization of oncogenic mRNAs and microRNAs (miRNAs). Particularly, we demonstrated that NCL enhances the maturation of specific miRNAs (including miR-21, miR-221 and miR-222) causally involved in cancer pathogenesis, aggressiveness, metastatic potential and resistance to several anti-neoplastic treatments.
Because of its oncogenic role and specific expression on cancer cell surface, NCL represents an attractive target for anti-neoplastic therapies. To produce a new anti-NCL molecule with significant potential for clinical applications, we took advantage of phage-display technology to isolate a fully human single chain Fragment variable (scFv), named 4LB5, which binds with high affinity to the RNA binding domain (RBD) of NCL. In our previous study we demonstrated that 4LB5 binds NCL on the surface of aggressive breast cancer cells and inhibits their proliferation both in vitro and in vivo, representing the prototype of a new class of immune-based anti-NCL compounds.
Since NCL expression has been previously reported on the cell surface of skin cancer cell lines and up-regulation of NCL-dependent microRNAs was described in human melanomas, the objective of this project was the assessment of 4LB5 as a potential tool for melanoma therapy.
To this aim, the recombinant scFv was expressed as His6-fusion protein in E.Coli and purified by affinity chromatography, as previously described. By using Enzyme-Linked Immunosorbent Assays (ELISA), we demonstrated a significant binding of 4LB5 to the cell surface of different melanoma cell lines of both human and mouse origins. Notably, inhibition of NCL expression by siRNA transfection reduced the binding of 4LB5 to the cell surface of these cell lines, further supporting its specificity against NCL. Then, we assessed the potential effects of 4LB5 treatment on cell proliferation. Colony formation assays demonstrated that 4LB5 significantly affected cell proliferation of both human and mouse melanoma cell lines.
Our results, in agreement with previously reported data, further support the potential activity of 4LB5 as a tool for cancer therapy, paving the way for additional investigations aimed to fully elucidate the molecular mechanisms affected by this scFv and resulting in its anti-neoplastic therapy in human melanomas. Furthermore, this study supports the idea that anti-NCL immunoagents might represent a class of new anti-cancer compounds with a strong clinical relevance for a wide range of human tumors.
Citation Format: Ashley Braddom, Timothy Richmond, Tyler Sheetz, Erika Reese, Anna Tessari, Kathleen Tober, Christin E. Burd, Claudia De Lorenzo, Edward W. Martin, Jr., Vincenzo Coppola, Michael F. Tweedle, Tatiana Oberyszyn, Carlo M. Croce, Dario Palmieri. Human anti-Nucleolin recombinant immunoagents as new potential tools for melanoma treatment. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C171.
Collapse
|
4
|
Teegarden M, Riedl K, Tober K, Schwartz S, Oberyszyn T. 25‐Hydroxyvitamin D and its C‐3 Epimer in a Mouse Model of Non‐Melanoma Skin Cancer. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.758.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Matthew Teegarden
- Food Science and TechnologyThe Ohio State UniversityColumbusOHUnited States
| | - Ken Riedl
- Food Science and TechnologyThe Ohio State UniversityColumbusOHUnited States
| | - Kathleen Tober
- PathologyThe Ohio State UniversityWexner Medical CenterColumbusOHUnited States
| | - Steven Schwartz
- Food Science and TechnologyThe Ohio State UniversityColumbusOHUnited States
| | - Tatiana Oberyszyn
- PathologyThe Ohio State UniversityWexner Medical CenterColumbusOHUnited States
| |
Collapse
|
6
|
Cooperstone J, Tober K, Riedl K, Riggenbach J, Francis D, Schwartz S, Oberyszyn T. Tomato carotenoids protect against UV‐induced cutaneous damage and tumor development in Skh‐1 hairless mice (645.7). FASEB J 2014. [DOI: 10.1096/fasebj.28.1_supplement.645.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Jessica Cooperstone
- Food Science and Technology The Ohio State UniversityColumbusOHUnited States
| | - Kathleen Tober
- Pathology The Ohio State University Wexner Medical CenterColumbusOHUnited States
| | - Ken Riedl
- Food Science and Technology The Ohio State UniversityColumbusOHUnited States
| | - Judith Riggenbach
- Pathology The Ohio State University Wexner Medical CenterColumbusOHUnited States
| | - David Francis
- Horticulture and Crop Science The Ohio State UniversityWoosterOHUnited States
| | - Steven Schwartz
- Food Science and Technology The Ohio State UniversityColumbusOHUnited States
| | - Tatiana Oberyszyn
- Pathology The Ohio State University Wexner Medical CenterColumbusOHUnited States
| |
Collapse
|
7
|
Martin J, Duncan FJ, Keiser T, Shin S, Kusewitt DF, Oberyszyn T, Satoskar AR, VanBuskirk AM. Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet‐B (UVB) ‐induced nonmelanoma skin cancer (NMSC). FASEB J 2008; 23:720-30. [DOI: 10.1096/fj.08-119628] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Jason Martin
- Department of SurgeryThe Ohio State UniversityColumbusOhioUSA
| | - F. Jason Duncan
- Department of SurgeryThe Ohio State UniversityColumbusOhioUSA
| | - Tracy Keiser
- Department of MicrobiologyThe Ohio State UniversityColumbusOhioUSA
| | - Samuel Shin
- Department of SurgeryThe Ohio State UniversityColumbusOhioUSA
| | - Donna F. Kusewitt
- Department of Veterinary BiosciencesThe Ohio State UniversityColumbusOhioUSA
| | | | | | - Anne M. VanBuskirk
- Department of SurgeryThe Ohio State UniversityColumbusOhioUSA
- Department of PathologyThe Ohio State UniversityColumbusOhioUSA
- Comprehensive Cancer CenterThe Ohio State UniversityColumbusOhioUSA
- Medical and Scientific AffairsTakeda Pharmaceuticals North AmericaDeerfieldILUSA
| |
Collapse
|